Anti-inflammatory and analgesic effects of the phosphodiesterase 4 inhibitor rolipram in a rat model of arthritis

European Journal of Pharmacology

Volumn 399, Issue 2-3, 2000, Pages 243-249

  Francischi, Janetti N ^a   Yokoro, Celina M ^a   Poole, S ^b   Tafuri, Wagner L ^a   Cunha, Fernando Q ^c   Teixeira, Mauro M ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Arthritis; Hyperalgesia; Oedema; Phosphodiesterase 4; Rolipram; TNF (tumor necrosis factor )

Indexed keywords

CYCLIC AMP; PHOSPHODIESTERASE; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; ROLIPRAM; TUMOR NECROSIS FACTOR ALPHA;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; CONTROLLED STUDY; EDEMA; FEMALE; HYPERALGESIA; INFLAMMATION; MEDIATOR RELEASE; NONHUMAN; PRIORITY JOURNAL; RAT;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANALGESICS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; EDEMA; FEMALE; HINDLIMB; INFLAMMATION; INTERLEUKIN-1; PHOSPHODIESTERASE INHIBITORS; RATS; ROLIPRAM; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034617379     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00330-7     Document Type: Article

References (23)

1. Au B.T., Teixeira M.M., Collins P.D., Williams T.J. Effect of PDE 4 inhibitors on zymozan-induced IL-8 release from human neutrophils synergism with prostanoids and salbutamol. Br. J. Pharmacol. 123:1998;1260-1266.
2. Breedveld F.C. Future trends in the treatment of rheumatoid arthritis: cytokine targets. Rheumatology (Oxford). 38(Suppl. 2):1999;11-13.
3. Capetola J.R., Shriver A.D., Rosenthale E.M. Suprofen, a new peripheral analgesic. J. Pharmacol. Exp. Ther. 214:1980;16-23.
4. Cash J.M., Klippel J.H. Second-line drug therapy for rheumatoid arthritis. N. Engl. J. Med. 330:1994;1368-1375.
5. Colpaert F.C., Meert T., De Witthand P., Schmitt P. Further evidence validating adjuvant arthritis as an experimental model of chronic pain in the rat. Life Sci. 31:1982;67-75.
6. Cunha F.Q., Teixeira M.M., Ferreira S.H. Pharmacological modulation of secondary mediator systems-cyclic AMP and cyclic GMP-on inflamatory hyperalgesia. Br. J. Pharmacol. 127:1999;671-678.
7. Feldman M., Taylor P., Paleolog E., Brennan F.M., Maini R.N. Anti-TNF-alpha therapy is useful in rheumatoid arthritis and Crohn's disease: analysis of the mechanism of action predicts utility in other diseases. Transplant. Proc. 30:1998;4126-4127.
8. Francischi J.N., Pereira L.M.S., Castro M.S. Cyclosporin effects on hyperalgesia and oedema presented by arthritic rats: role of the Central Nervous System. Braz. J. Med. Biol. Res. 30:1997;101-111.
9. Kasyapa C.S., Stentz C.L., Davey M.P., Carr D.W. Regulation of IL-15-stimulated TNF-a production by rolipram. J. Immunol. 163:1999;2836-2843.
10. Moreland L.W., Baumgartner S.W., Schiff M.H., Tindall E.A., Fleischmann R.M., Weaver A.L., Ettlinger R.E., Cohen S., Koopman W.J., Mohler K., Widmer M.B., Blosch C.M. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 337:1997;141-147.
11. Nyman U., Müssener A., Larsson E., Lorentzen J., Klareskog L. Amelioration of collagen II-induced arthritis in rats by the type IV phosphodiesterase inhibitor Rolipram. Clin. Exp. Immunol. 108:1997;415-419.
12. Owen R.T. Adjuvant induced poliarthritis - an overview. Methods and Findings in Experimental and Clinical Pharmacology. 2:1980;199-204.
13. Pearson C.M. Development of arthritis, periarthritis and periostitis in rats given adjuvants. Proc. Soc. Exp. Biol. Med. 91:1956;95-101.
14. Pearson C.M., Wood F. Studies of arthritis and other lesions induced in rats by the injection of mycobacterial adjuvant. Am. J. Pathol. 42:1963;93-95.
15. Procopio D.O., Teixeira M.M., Camargo M.M., Travassos L.R., Ferguson M.A., Almeida I.C., Gazzinelli R.T. Differential inhibitory mechanism of cyclic AMP on TNF-alpha and IL-12 synthesis by macrophages exposed to microbial stimuli. Br. J. Pharmacol. 127:1999;1195-1205.
16. Rees G.S., Gee C.K., Ward H.L., Ball C., Tarrant G.M., Poole S., Bristow A.F. Rat tumour necrosis factor-alpha: expression in recombinant Pichia pastoris, purification, characterization and development of a novel ELISA. Eur. Cytokine Network. 10:1999;383-392.
17. Ross S.E., Williams R.O., Mason L.J., Mauri C., Marinova-Mutafchieva L., Malfait A.M., Maini R.N., Feldman M. Supression of TNF-α expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by Rolipram. J. Immunol. 159:1997;6253-6259.
18. Sekut L., Yarnall D., Stimpson S.A., Noel L.S., Bateman-Fite R., Clark R.L., Brackeen M.F., Menius J.A. Jr., Connoly K.M. Anti-inflamatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflamation. Clin. Exp. Immunol. 100:1995;126-132.
19. Sewell K.L., Trentham D.E. Pathogenesis of rheumatoid arthritis. Lancet. 341:1993;283-286.
20. Tatsuo M.A.K.F., Carvalho W.M., Silva C.V., Miranda A.E.G., Ferreira S.H., Francischi J.N. Analgesic and antiinflamatory effects of dipyrone in rat adjuvant arthritis model. Inflammation. 18:1994;399-405.
21. Teixeira M.M., Gristwood R.W., Cooper N., Hellewell P.G. Phosphodiesterase (PDE)4 inhibitors: anti-inflamatory drugs of the future? Trends Pharmacol. Sci. 18:1997;164-167.
22. Torphy T.J. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am. J. Respir. Crit. Care Med. 157:1998;351-370.
23. Verghese M.W., McConnell R.T., Strickland A.B., Gooding R.C., Stimpson S.A., Yarnall D.P., Taylor J.D., Furdon P.J. Differential regulation of human monocytes-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors. J. Pharmacol. Exp. Ther. 272:1995;1313-1320.